Jasper Therapeutics, Inc.
No SEC Form 4 filings for $JSPR in the last 30 days.
See all $JSPR insider activity →Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030204901ex99-1.htm PRESS RELEASE, DATED AUGUST 14, 2026 Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio
Jasper Therapeutics (JSPR) reported Q2 2026 results and a corporate update after completing its all-stock acquisition of Kira Pharmaceuticals on July 16, 2026. The company raised about $132M via a private placement of non-voting convertible preferred stock. Cash was $7.3M at June 30. Net loss was $2.8M. Pipeline updates include KP-104, briquilimab, and KP-701.
Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001788028 0001788028 2026-07-31 2026-07-31 0001788028 JSPR:VotingCommonStockParValue0.0001PerShareMember 2026-07-31 2026-07-31 0001788028 JSPR:RedeemableWarrantsEachTenWarrantsExercisableForOneShareOfVotingCommonStockAtExercisePriceOf115.00Member 2026-07-31 2026-07-31 iso4
Over the past 7 days, alphai's AI scored 2 news stories mentioning JSPR (Jasper Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent JSPR coverage spans financial news, corporate actions and mergers & acquisitions.
The filing combines dilution/capital raise details with a major portfolio expansion via Kira, and reiterates near-term clinical milestones and cash position.
Financing plus post-acquisition pipeline milestones reduce near-term funding risk and set specific FDA interaction and trial timing catalysts.
This is a routine corporate governance disclosure with no new operating or financial guidance.
Deal completion plus $132M financing extends runway to 2H 2028 and expands a complement and immunology pipeline, supporting near-term risk reduction but increasing execution risk.
Financing plus deal close extends runway and reshapes the pipeline, likely supporting near-term liquidity confidence while increasing execution risk.
alphai scores every news story that mentions JSPR with an AI model for sentiment and relevance, and aggregates insider trades from Jasper Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030204901ex99-1.htm PRESS RELEASE, DATED AUGUST 14, 2026 Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio
6 min readJasper Therapeutics (JSPR) reported Q2 2026 results and a corporate update after completing its all-stock acquisition of Kira Pharmaceuticals on July 16, 2026. The company raised about $132M via a private placement of non-voting convertible preferred stock. Cash was $7.3M at June 30. Net loss was $2.8M. Pipeline updates include KP-104, briquilimab, and KP-701.
6 min readJasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001788028 0001788028 2026-07-31 2026-07-31 0001788028 JSPR:VotingCommonStockParValue0.0001PerShareMember 2026-07-31 2026-07-31 0001788028 JSPR:RedeemableWarrantsEachTenWarrantsExercisableForOneShareOfVotingCommonStockAtExercisePriceOf115.00Member 2026-07-31 2026-07-31 iso4
2 min readJasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, forming a combined Nasdaq-listed company under ticker JSPR. The deal includes a $132M private placement and a $12M Mirador out-licensing payment on signing, funding operations through H2 2028. Pipeline includes KP-104, briquilimab, and KP-701 with upcoming clinical milestones.
5 min readJasper Therapeutics (NASDAQ:JSPR) closed a deal with Kira and completed a private placement of non-voting convertible preferred stock raising about $132 million gross. The company expects cash to fund operations through 2H 2028. Jasper out-licensed Kira’s KP-301 and KP-402 to Mirador for $12 million upfront plus milestones. JSPR shares rose 20.67% to $0.9250.
5 min readJasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ea029822901ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED JULY 16, 2026, BY AND AMONG JASPER THERAPEUTICS, INC., KIRA HOLDCO INC. AND KIRA PHARMACEUTICALS Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: JASPER THERAPEUTICS, INC., a Delaware corporation; KIRA HOLDCO INC.,
6 min readJasper Therapeutics (NASDAQ: JSPR) announced that director Christian Nolet resigned from its Board of Directors and associated committees, effective May 15, 2026. The company stated that his resignation was not due to any disagreements regarding operations or policies. Concurrently, Svetlana Lucas, Ph.D. was appointed to the Board’s Audit Committee.
2 min readNEW YORK, Nov. 22, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Driven Brands Holdings, Inc. ( NASDAQ:DRVN ) and Jasper Therapeutics, Inc ( NASDAQ:JSPR ) on behalf of long-term ...
2 min readLOS ANGELES, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
2 min readNEW YORK, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Jasper Therapeutics, Inc. ( NASDAQ:JSPR ) , KBR, Inc. ( NYSE:KBR ) , Spirit ...
3 min read
